Author

J. C. Chamcheu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Assay:proteomics· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

B. M. Nagalo· 4 shared C. C. Simoes· 3 shared C. Dumbauld· 3 shared O. Barro· 3 shared S. R. Post· 3 shared A. Basnakian· 2 shared M. Borad· 2 shared M. J. Cannon· 2 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

B. M. Nagalo

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers

B. M. Nagalo, Y. Zhou, E. L. Loeuillard, C. Dumbauld, O. Barro, N. Elliott, A. T. Baker, M. Arora, J. M. Bogenberger, N. Meurice, J. Petit, P. L. S. Uson Junior, F. Aslam, J. C. Chamcheu, C. C. Simoes, , M. Borad

This study characterizes Morreton virus (MORV) as a safe and effective oncolytic virotherapy for liver cancers, showing tumor regression in animal models with lower doses than VSV.

Hepatology · Jun 1, 2023Peer-reviewedImmunology

In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis

Y. Zhang, M. Tesfay, K. U. Ferdous, M. Taylor, M. N. Gabere, C. C. Simoes, C. Dumbauld, O. Barro, A. Graham, C. L. Washam, D. Alkam, A. Gies, J. C. Chamcheu, S. D. Byrum, S. R. Post, , B. M. Nagalo

This study evaluates the in vivo safety and immunoactivity of Jurona virus in hepatocellular carcinoma using proteogenomic analysis, showing tumor regression and enhanced immune responses.

bioRxiv · Sep 9, 2022 · PreprintImmunology

Identification of potential inhibitors of cutaneous Melanoma and Non-Melanoma skin cancer cells through in vitro and in silico screening of a small library of Phenolic compounds

S. T. Boateng, T. Roy, M. E. Agbo, S. Banang-Mbeumi, R.-C. N. Chamcheu, M. Bramwell, L. K. Pham, K. E. Jackson, R. A. Hill, B. M. Nagalo, T. Efimova, J. Fotie, J. C. Chamcheu

This study screens a small library of phenolic compounds in vitro and in silico to identify potential inhibitors of melanoma and non-melanoma skin cancer cells, finding several compounds with significant antitumor activity and selectivity.

bioRxiv · Feb 28, 2022 · PreprintPharmacology & Toxicology

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

B. M. Nagalo, Y. Zhang, M. A. Taylor, C. C. Simoes, C. Dumbauld, M. N. Gabere, O. Barro, J. C. Chamcheu, S. R. Post, T. J. Kelly, M. J. Borad, M. J. Cannon, A. Basnakian

This study shows that intratumoral MMR vaccine injections inhibit tumor growth and improve survival in mouse cancer models by enhancing cytotoxic T-cell responses.

bioRxiv · Feb 25, 2022Immunology